German Cancer Consortium (DKTK) Dresden, Germany; Dept. of Radiation Oncology, Technische Universität Dresden, Germany; OncoRay, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Germany; German Cancer Research Center (DKFZ) Heidelberg, Germany.
German Cancer Consortium (DKTK) Dresden, Germany; OncoRay, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; German Cancer Research Center (DKFZ) Heidelberg, Germany.
Adv Drug Deliv Rev. 2017 Jan 15;109:63-73. doi: 10.1016/j.addr.2016.02.002. Epub 2016 Feb 12.
Inactivation of cancer stem cells (CSCs) is of utmost importance for tumor cure after radiotherapy. An increasing body of evidence complies with a higher radioresistance of CSCs compared to the mass of tumor cells, supporting the use of CSC related biomarkers for prediction of radiotherapy outcome. Treatment individualization strategies for patient groups with vastly different risk of recurrence will most likely require application of more than one biomarker. Specifically, inclusion of established biomarkers like tumor size for primary radio(chemo)therapy or human papilloma virus (HPV) infection status in head and neck squamous cell carcinoma seems to be of very high relevance. The high heterogeneity of CSC subclones along with changes of the functional behavior of individual tumors under treatment underlines the importance of the selection of the optimal timepoint(s) of biomarker evaluation, but also provides a potential therapeutic target for combined treatment approaches with irradiation.
癌症干细胞 (CSC) 的失活对于放疗后的肿瘤治愈至关重要。越来越多的证据表明，CSC 比肿瘤细胞群具有更高的放射抗性，这支持使用 CSC 相关生物标志物来预测放疗结果。对于复发风险差异很大的患者群体，治疗个体化策略很可能需要应用多种生物标志物。具体来说，对于原发性放（化）疗，纳入肿瘤大小等已确立的生物标志物，或在头颈部鳞状细胞癌中纳入人乳头瘤病毒 (HPV) 感染状态，似乎具有非常高的相关性。CSC 亚克隆的高度异质性以及在治疗下个别肿瘤功能行为的变化，凸显了选择最佳生物标志物评估时间点的重要性，但也为联合放疗的治疗方法提供了潜在的治疗靶点。
